Breast Cancer
News
MRI screening cost effective for women with dense breasts
For women with extremely dense breasts, screening with MRI alone every 4 years is cost effective and delivers the greatest benefit, the first...
Conference Coverage
Many patients, doctors unaware of advancements in cancer care
“These patients must be spared the traumatic effects of being handed a death sentence that no longer reflects the current reality,” said Dr....
News
Novel trastuzumab duocarmazine significantly improved survival in advanced HER2-positive breast cancer
Trastuzumab duocarmazine is a novel HER2-targeting antibody-drug conjugate which, according to the results of the TULIP trial recently presented...
Conference Coverage
Treatment shows 'important improvements' in triple-negative breast cancer
Survival of patients without an initial diagnosis of triple-negative breast cancer was better with the antibody-drug conjugate, compared with...
News
Better survival with extended letrozole in early-stage breast cancer
Guidelines for duration of endocrine therapy ‘should be updated.’
Conference Coverage
TULIP trial shows extended survival in HER2+ metastatic breast cancer
Progression-free survival was up to 7 months in some cases, but with adverse events.
Conference Coverage
Study supports add-on therapy for germline and wildtype BRCA mutations
The findings put to rest the notion that patients with germline BRCA mutations would not benefit from carboplatin treatment because of sensitivity...
Conference Coverage
Twelve-month overall survival benefit with ribociclib for metastatic breast cancer
It’s the first phase 3 trial to report a median overall survival beyond 5 years in advanced breast cancer.
News
Call for a move or boycott of big Texas cancer meeting
“I think that if Texas officials understood that when they pass laws inhospitable to women, we will not hold a major conference about women’s...
News
Patients panic as docs cut off breast cancer drug
Experts say discontinuing atezolizumab is not advised if a patient is responding or is stable.